Application 1049
M-VAX™ - a treatment for patients with advanced Stage III melanoma
|
Application No. | 1049 |
| Application Name | M-VAX™ - a treatment for patients with advanced Stage III melanoma |
| Advisory Panels | Dr Paul Craft (Chair and MSAC member) Professor Bruce Barraclough (MSAC member) Professor Jane Hall (MSAC member) Dr Philip Clarke (Royal Australian College of General Practitioners nominee) Professor Peter Hersey (co-opted member) Professor Michael O'Rourke (Royal Australasian College of Surgeons nominee) Associate Professor Ruth Salom (Royal Australasian College of Pathologists nominee) Mr Clive Deverall (Consumers' Health Forum of Australia nominee) |
| Date Received by MSAC Secretariat | September 2001 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | This assessment was considered by the MSAC at the 21 August 2002 meeting. The MSAC recommended that on the strength of evidence pertaining to M-VAX™, a treatment for patients with advanced Stage III melanoma, public funding should not be supported for this procedure. |
| Stage 4 - Decision | Endorsed by the Minister for Health and Ageing 8 October 2002 |
| Stage 5 - Implementation |  |
Page currency, Latest update: 03 April, 2009
